Orex­i­gen posts a ‘for sale’ sign in the yard as weak Con­trave sales raise con­cerns

The end may not be far off for Orex­i­gen $OREX, one of the three biotechs which man­aged to get an obe­si­ty drug in­to the US …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.